Bioavailability in rats of human recombinant tissue plasminogen activator after subcutaneous and intramuscular injection.
The bioavailability of human recombinant tissue plasminogen activator (rt-PA) in rats was measured after subcutaneous (s.c.) and intramuscular (i.m.) injection. Rt-PA was absorbed after both i.m. and s.c. injection, giving peak plasma concentrations within 30 min and 1 h, respectively, with detectable concentrations up to 6 h. These peak values of bioavailable t-PA were obtained in a functional fibrin plate assay of euglobulin precipitates and expressed as +88% and +243% (for s.c. and i.m. routes respectively) above basal rat fibrinolytic activity. Prior injection of rt-PA, s.c. or i.m., significantly reduced the weights of thrombi induced in the inferior vena cava after injection.
D000818:Animals; D001682:Biological Availability; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D013923:Thromboembolism / Q000517:prevention & control; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator